Table 1.
BIII 890 CL binding to receptors
| Target | IC50, nM |
|---|---|
| BTX | 49 |
| TTX | >10,000 |
| NMDA (MK-801, glutamate, glycine), AMPA | >10,000 |
| Ca2+ dihydropyridine | >10,000 |
| Ca2+ (verapamil) | 2,680 |
| Ca2+ (diltiazem) | 719 |
| K+ channel (voltage dep., ATP sensit., Ca2+ dep.) | >10,000 |
| Cl− channel, GABAA, glycine | >10,000 |
| Adrenergic (α1, α2, β1, β2), dopaminergic (D1, D2, D3, D4) | >10,000 |
| Serotoninergic (5-HT1, 5-HT2, 5-HT3) | >10,000 |
| Adenosine (A1, A2), histamine (H1, H3) | >10,000 |
| Muscarinic (M1, M2, M3, M4), nicotinic (α4β2) | >10,000 |
| Cholecystokinin, thromboxane A2, LTB4, PAF | >10,000 |
| Endothelin, angiotensin, bradykinin, TRH | >10,000 |
| VIP, NK1, NPY2, insulin, galanin, phorbol ester | >10,000 |
| Glucocorticoid, estrogen, testosterone, progesterone | >10,000 |
| Opiate: delta | >10,000 |
| kappa | 1,000 |
| mu | 3,000 |
| Sigma (DTG, pentazocine) | 1,000 |
| EGF TK, calcineurin, calpain, NOS | >10,000 |
| MAOA, MAOB, PKCα, PKCβ | >100,000 |